Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
3.900
+0.190 (5.12%)
At close: Jan 21, 2025, 4:00 PM
2.690
-1.210 (-31.03%)
Pre-market: Jan 22, 2025, 8:53 AM EST
Lisata Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
32.74M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
LSTA News
- 7 days ago - Lisata Therapeutics to Present at the 2025 Sequire Investor Summit - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year' - GlobeNewsWire
- 2 months ago - Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration - GlobeNewsWire
- 2 months ago - Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 - GlobeNewsWire
- 2 months ago - Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events - GlobeNewsWire